Hesco acetic acid capofen net obtained "drug registration certificate"

On August 17th, Haisco announced that Its wholly-owned subsidiary, Liaoning Haisco, had recently received the "Drug Registration Certificate" issued by the State Drug Administration for the net injection of acetic acid carpofen.
-adaptive disorders are suitable for adult patients and children (three months and more): 1, empirical treatment of neutral granulocyte reduction, suspected fungal infections in patients with fever;
The role of this product in endovascularitis, myelitis and meningitis caused by Candivitis infection has not been studied; 3, treatment of candivitis of the esopteriology; 4, treatment is ineffective or insatiable for other treatments (e.g., mesothromycin B, mycomycin B lipids, icingcomycin) patients with invasive astromycin.
has not yet studied the role of this product as the initial treatment of invasive asmycinosis.
capofen acetate is a semi-synthetic lipid peptide (echiatoxin) compound synthesized from Glarea Lozoyensis fermentation products and is the first new antifungal drug for echinocycin.
has the characteristics of wide antibacterial spectrum, long half-life, high binding rate with human serum protein, fewer adverse reactions and good patient tolerance, and is a clinically urgently needed anti-deep fungal infection drug.
, in 2001 the FDA approved Merck and Co., Inc.'s cancidas ®, 50mg and 70mg) for injection, and in 2007 Merck Sharp and Dohme Corp's Cosses ® entered China.
is the fourth of its kind in China.
million yuan in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals, according to the company's internal network data.
.